Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

46.63 +0.16 (+0.34%)
Official Closing Price Updated: 7:00 PM EST, Nov 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
82 83 Next >
Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes
From Bristol Myers Squibb
Via Business Wire
AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns
Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design... 
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
BMY CEO Expects Cancer Drug Opdivo To Drive Strong Sales In 2025
Via Stocktwits
Earnings Scheduled For October 30, 2025
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership
BioNTech reports a Q3 loss but boosts 2025 revenue forecast to €2.6–2.8 billion, driven by Bristol Myers collaboration and cost optimization. 
Via Benzinga
Cleveland-Cliffs, Meta And Rocket On CNBC's 'Final Trades'
Cleveland-Cliffs shares gained 1.4% to close at $12.43 on Friday while Bristol-Myers Squibb shares gained 1% to close at $46.07. 
Via Benzinga
Bristol Myers Squibb Co (NYSE:BMY) Presents a Compelling Value Investment Case
Bristol Myers Squibb (BMY) offers strong value with a low P/E ratio, high profitability, and a robust 5.38% dividend yield, despite patent challenges. 
Via Chartmill
Topics Intellectual Property
Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes
From Bristol Myers Squibb
Via Business Wire
Amgen Solidifies Biotech Dividend Prowess with $2.38 Q4 2025 Payout
Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant... 
Via MarketMinute
Topics Intellectual Property
Bristol-Myers Squibb Co (NYSE:BMY) Offers a Compelling Mix of High Yield and Dividend Growth
Discover Bristol-Myers Squibb (BMY), a top dividend stock with a strong 5.82% yield, consistent growth, and solid profitability for reliable income. 
Via Chartmill
Discover which S&P500 stocks are making waves on Thursday.
Curious about the top performers within the S&P500 index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
Bristol-Myers Squibb (BMY) Stock Trades Up, Here Is Why
Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 4.3% in the morning session after the company posted third-quarter financial results that beat expectations and raised its... 
Via StockStory
Topics Artificial Intelligence Earnings
Bristol Myers' New Treatments Drive Q3 Beat — And The Company's Raising Its Outlook
Bristol Myers beats Q3 forecasts with $12.22 billion revenue and a higher 2025 sales outlook, driven by strong demand for Reblozyl, Camzyos, and Breyanzi. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q3
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 2.8% year on year to $12.22 billion. The company’s full-year... 
Via StockStory
Bristol Myers Squibb Co (NYSE:BMY) Q3 2025 Earnings Beat Estimates
Bristol Myers Squibb Q3 2025 earnings beat estimates with $1.63 EPS and $12.22B revenue, driven by strong new product sales. 
Via Chartmill
Topics Earnings
Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday?
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome... 
Via Benzinga
Topics Economy
Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
From Bristol Myers Squibb
Via Business Wire
What to Expect from Bristol-Myers Squibb's Earnings
 
Via Benzinga
Bristol-Myers Squibb (BMY) To Report Earnings Tomorrow: Here Is What To Expect
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday morning. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
3 Dividend-Paying Drug Stocks to Buy at a Discount
Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying? 
Via The Motley Fool
Topics Intellectual Property
Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus
From Bristol Myers Squibb
Via Business Wire
Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal
Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash. 
Via Benzinga
Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
From Bristol Myers Squibb
Via Business Wire
Inhibrx Stock Soars on Breakthrough Chondrosarcoma Trial Results: A New Dawn for Rare Cancer Treatment
San Diego, CA – October 24, 2025 – Inhibrx (NASDAQ: INBX) shares have surged dramatically, skyrocketing over 70% in pre-market and after-hours trading, following the announcement of overwhelmingly... 
Via MarketMinute
Checking In on The Trade Desk, Bristol Myers Squibb, and Other Stocks
Motley Fool analysts Karl Thiel, Rick Munarriz, and Tim Beyers offer up three stocks that face dark clouds they can see through. 
Via The Motley Fool
Topics Workforce
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the... 
Via MarketMinute
Why Replimune Stock Was Soaring Today
An investigational treatment, used in combination with another cancer medication, took an important step forward after several setbacks. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
82 83 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.